🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquarePet photos thread v2 — what worked for you?

Pet photos thread v2 — what worked for you?

Dr.MetabolicMD Sun, Dec 29, 2024 at 2:39 AM 15 replies 1,818 viewsPage 1 of 3
This thread is more than 17 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Dec 29, 2024 at 2:39 AM#1

My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my material.

The bit I cannot resolve on my own is how to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases.

Numbers rather than impressions, if you have them.

9 12SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 6 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Dec 29, 2024 at 4:23 AM#2

Short answer first, then the reasoning. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

10 13HPLC_Greg, LibrarianMeg, bri_stats and 7 others
Reply Quote Save Share Report
pam_columbus
Member
312
1,345
Aug 2024
Columbus, OH
Dec 29, 2024 at 6:07 AM#3
labquiet_amy said:
The gap between trial results and real-world results is consistent and it is not fraud.
labquiet_amy said:
...regarding the trial evidence...

I think this is an underappreciated point. To expand on it with some data:

A recent meta-analysis of 15 RCTs (n=12,300) found that the trial evidence was associated with a clinically meaningful effect size across diverse patient populations[1].

The NNT was 12, which is comparable to antihypertensives for stroke reduction. That's a strong clinical argument for this approach.

11 14Dr.LipidDallas, alex_tucson, kevin_tulsa and 8 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
PharmHunterJen
Member
567
2,345
Jul 2024
Illinois
Dec 29, 2024 at 7:51 AM#4
Dr.MetabolicMD said:
My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…

Can confirm the pattern Dr.MetabolicMD describes. Read four things before the headline number. The population, because trial populations are selected and supported in ways that real cohorts are not. The comparator, because "better than placebo" and "better than the current standard" are different claims and get reported identically. The primary endpoint as pre-registered, because a secondary endpoint promoted after the fact is a hypothesis rather than a finding. And the completion rate, because a large effect in the half of participants who finished is a different result from a large effect in everybody enrolled.

Last edited: Dec 29, 2024 at 1:51 PM
12 15Dr.PainCLE, mike_mealprep, NicoleRaleigh and 9 others
Reply Quote Save Share Report
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
Dec 29, 2024 at 6:05 PM#5

Clinical perspective, offered as context rather than as advice.

Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:

  1. Point estimate (HR/RR/OR) — center of the diamond
  2. Confidence interval width — precision of the estimate
  3. I² statistic — heterogeneity across studies
  4. Individual study weights — are results driven by one large trial?
  5. Prediction interval — range of plausible true effects in future settings

The the trial evidence meta-analysis shows a pooled RR of 0.80 (95% CI 0.68-0.85), I²=53%. This is a robust and consistent effect.

13 16MeganSA_TX, LarryQC_SD, wanda_boise and 10 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register